ClinicalTrials.gg
Sign In
Not yet recruitingNCT06897969Updated Apr 1, 2025

Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment

A Phase 4 interventional study of Triamcinolone Acetonide 1 ml of 40 mg/mL suspension and Verapamil Injection in Keloid Scars, sponsored by Nishtar Medical University. Not yet recruiting at 1 site in Pakistan. Open to participants aged 10 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Nishtar Medical University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.
Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
10 Years to 50 Years
Sex
All
01

Study summary

This study aims to compare the efficacy of intralesional triamcinolone and verapamil in patients presenting with keloid at our local setting. The results will guide us towards better management of keloids by choosing the more appropriate treatment. Adequate treatment will reduce significant emotional and physical distress in patients. We hypothesized that mean reduction in Vancouver Scar Score is higher in triamcinolone acetonide group compared to verapamil after three months of treatment.

02

Conditions studied

  • Keloid Scars

Browse trials for

Keywords

  • Keloid
  • Vancouver scar scale
  • Triamcinolone
  • Verapamil
  • Intralesional injection
03

In context

Keloid

138 studies on the registry are indexed under Keloid; 26 are open to participants now.

This study's planned enrollment of 60 is above the median of 30 across 109 interventional studies indexed under Keloid.

Browse Keloid studies →

Lead sponsor

Nishtar Medical University is the lead sponsor of 29 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • size of keloid1-5 cm,
  • on any site of the body,
  • duration less then five years and
  • baseline Vancouver scar score of more the or equal to 5

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women,
  • family history of keloids,
  • acromegaly, and
  • congestive cardiac diseases
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Verapamil Treatment

    One ml (2.5 mg) of Intralesional Verapamil Injection will be administered monthly. The injections will be administered with an insulin syringe of 27-gauge needle. Administration of the treatment medication will be continued till the keloid is flattened or TOTAL DURATION of three months.

    Drug: Verapamil Injection

  • Experimental
    Triamcinolone Treatment

    Intralesional Triamcinolone acetonide (40mg) will be administered monthly. The injections will be administered with an insulin syringe of 27-gauge needle. Administration of the treatment medication will be continued till the keloid is flattened or TOTAL DURATION of three months.

    Drug: Triamcinolone Acetonide 1 ml of 40 mg/mL suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Vancouver Scar Score

    The Vancouver Scar scale assesses four parameters of vascularity, pigmentation, pliability and height. The total score ranges from 0 - 13.

    Time frame: Vancouver Scar score will be measured at baseline (before treatment assignment) and then 4-weeks after completion of treatment - 16-weeks after randomization.

07

Study locations

1 site
08

References and documents

Publications

  • Kuang J, An P, Li W. Comparative efficacy and safety of verapamil and triamcinolone in keloid and hypertrophic scar treatment: a meta-analysis. J Cosmet Laser Ther. 2021 Feb 17;23(1-2):26-34. doi: 10.1080/14764172.2021.1950765. Epub 2021 Jul 18. PubMed 34278918 ↗
  • Uzair M, Butt G, Khurshid K, Pal SS. Comparison of intralesional triamcinolone and intralesional verapamil in the treatment of keloids. Our Dermatol Online. 2015;6(3):280-4.
  • Saki N, Mokhtari R, Nozari F. Comparing the Efficacy of Intralesional Triamcinolone Acetonide With Verapamil in Treatment of Keloids: A Randomized Controlled Trial. Dermatol Pract Concept. 2019 Jan 31;9(1):4-9. doi: 10.5826/dpc.0901a02. eCollection 2019 Jan. PubMed 30775139 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared to protect patient confidentiality and comply with ethical and regulatory guidelines. Additionally, the study design does not include provisions for public data sharing.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Sep 2025, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Mar 27, 2025
StartEst.
Apr 1, 2025
Primary completionEst.
Sep 30, 2025
CompletionEst.
Sep 30, 2025
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06897969
Lead sponsor
Nishtar Medical University
Responsible party
Dr. Asma Batool (Principal Investigator, Nishtar Medical University) — Principal investigator
First posted
Mar 27, 2025
Start date
Apr 1, 2025 (estimated)
Primary completion
Sep 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Apr 1, 2025

Study contacts

Dr. Asma Batool, MBBS
Contact
abatool709@gmail.com
923470416435
Dr. Aliya Akhtar, FCPS
study director · Nishtar Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Other studies in this condition

Keloid →

Other studies from this sponsor

Nishtar Medical University

Start the discussion